LabCorp Receives FDA Green Light for a New Type of COVID-19 Test Using Fewer Reagents - COVID-19 Clinical Trial
Breaking News | COVID-19

LabCorp Receives FDA Green Light for a New Type of COVID-19 Test Using Fewer Reagents

LabCorp has received a new emergency authorization from the FDA for a COVID-19 test that does not require the use of chemical reagents to free the coronavirus’s RNA from a sample.

By using a heat-based process that traps and concentrates viral particles in order to coax out their genetic material for sequencing, the company can avoid relying on the extraction reagents required to perform most RT-PCR tests—products that have fallen into short supply over the course of the pandemic.

LabCorp said the high-throughput method will improve its efficiency and streamline the use of its resources while reducing testing delays linked to bottlenecks within the reagent supply chain. The company has previously received amendments to its test’s authorization to allow for the use of different extraction methods in the face of shortages. 


Regeneron Trial Finds Covid-19 Therapy Improved Symptoms

A descriptive analysis of Regeneron Pharmaceuticals’ Phase I/II/III clinical trial has found that its antibody cocktail REGN-COV2 lowered viral load and the time to symptoms improvement in non-hospitalised Covid-19 patients.The therapy also demonstrated positive trends in decreasing medical visits.During the ongoing, randomised, double-blind trial, the combination of REGN-COV2 and usual standard-of-care is being compared to placebo plus standard-of-care.

Regeneron noted that trial participants were given a one-time infusion of 8g or 2.4g of REGN-COV2 or placebo.Data from the descriptive analysis is based on the findings from the initial 275 patients. The analysis evaluated anti-viral activity with the therapy and is intended to detect patients who are most likely to benefit from treatment.

Share this:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Scroll to Top

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.